Summary
The National Pharmaceutical Pricing Authority has capped trade margins on three non-scheduled anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab, at 30 per cent of the price to distributor. It used its extraordinary powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
Revised prices for 137 brands take effect from 9 November 2026. The NPPA found intermediaries had been adding an average mark-up of about 170 per cent. Critics welcome the move but warn that it does not control manufacturers' own prices, as the rise in the price of the breast cancer drug ribociclib shows despite earlier margin limits.
They argue it must be paired with wider insurance, public cancer services and support for generics.
WHY IT MATTERS FOR UPSC & STATE PCS
The NPPA's order of 17 October 2026 capping trade margins on three non-scheduled anti-cancer drugs takes effect on 9 November 2026. Editorial and expert commentary has debated whether margin caps can make cancer treatment genuinely affordable.
Standard News
The Cap Fixes the Middle of the Chain. The Source Is Still Open.
India's new trade margin cap tackles a real abuse. The NPPA found that intermediaries such as stockists, distributors and hospital pharmacies were adding an average mark-up of about 170 per cent to three important cancer drugs. From 9 November 2026, that mark-up is limited to 30 per cent of the price at which manufacturers sell to distributors. The question is whether that is enough.
Why the Cap Matters
The margin cap is the right first move. It targets the part of the price that adds the least value: the distribution chain. It has worked before. When the NPPA used the same tool in 2019 on 42 cancer drugs, prices fell across 526 brands and a 2021 study found an average drop of 41 per cent in maximum retail prices.
It also avoids the risk of a direct price ceiling. When coronary stent prices were cut sharply in 2017, multinational firms sought to withdraw advanced products from the Indian market. A margin cap leaves the manufacturer's price untouched, so it is less likely to provoke such retreats.
Why the Cap Is Not Enough
The weakness is in the same design. Because the cap is measured from the manufacturer's selling price, a company can simply raise that price. For patented drugs, where generics cannot compete, the manufacturer sets the base price with little restraint.
The breast cancer drug ribociclib, whose margins were restricted in 2019, reportedly still rose from ₹58,000 to ₹78,000 a month. There are other gaps. Manufacturers may give steep discounts on a few units to select corporate hospitals while selling most stock at higher prices, distorting the market price regulators see.
Hospitals may recover lost margin through room rent and other charges. And drugs are only part of the burden: a 2023 study of over 12,000 cancer patients found average annual out-of-pocket spending of about ₹3.31 lakh, much of it on care outside hospital admission, travel and lost income.
TAN's Position
TAN supports the cap and would keep it, but as one part of a broader package rather than a solution in itself. First, manufacturers' prices to distributors and their discounts should be disclosed, so that any rise in base prices is visible.
Second, for patented cancer drugs, the government should negotiate prices, considering voluntary licensing and the clinical benefit a drug adds. Third, financial protection should extend beyond hospital admissions, with Ayushman Bharat PM-JAY covering more of the outpatient spending that dominates cancer costs.
What would change this position? If disclosure showed manufacturers systematically raising base prices to absorb the cap, a direct ceiling on manufacturer prices would become justified despite its risks.
Why This Matters for the Exam
Drug pricing debates usually treat regulation as all or nothing. The trade margin cap shows that the useful question is which link in the price chain to target and what else must change for savings to reach the patient.
Quick Facts
Key numbers & takeaways — revise these first
-
The NPPA invoked Paragraph 19 of the DPCO, 2013, which allows price intervention in extraordinary circumstances in the public interest.
-
The cap limits the trade margin to 30 per cent of the price to distributor, with GST added.
-
It covers Trastuzumab, Osimertinib and Durvalumab across 137 brands, effective 9 November 2026.
-
Intermediaries were adding an average mark-up of about 170 per cent.
-
In 2019, trade margin rationalisation on 42 cancer drugs cut prices across 526 brands, with a 2021 study finding an average MRP reduction of 41 per cent.
-
A 2023 study of over 12,000 Indian cancer patients found average annual out-of-pocket spending of about ₹3.31 lakh.
-
Manufacturers who overcharge must repay the excess with 15 per cent interest under the Essential Commodities Act, 1955.
-
Trastuzumab treats HER2-positive breast and stomach cancers; Osimertinib treats EGFR-mutated lung cancer; Durvalumab is an immunotherapy drug.
Connect the dots for your UPSC preparation.
Standard news covers the event. Log in to read our comprehensive analysis and uncover the hidden constitutional, structural, and ethical dimensions of this topic:
The full case for direct control of manufacturer prices, built on the ribociclib example and hospital discount practices
The equally strong case for restraint, drawing on the 2019 success of margin caps and the 2017 stent withdrawals
TAN's three-part position on disclosure, negotiated prices and outpatient insurance cover
The specific evidence that would justify moving to direct manufacturer price ceilings
Included in this analysis
Join thousands of aspirants analyzing the news deeply.
Unlock Premium — Rs.699 AnnuallyDon't have an account? Sign up for free